|

SVN53-67/M57-KLH Peptide Vaccine Clinical Trials

1 actively recruiting trial across 1 location

Also known as: SurVaxM

Pipeline

Phase 2: 1

Top Sponsors

  • Roswell Park Cancer Institute1

Indications

  • Digestive System Neuroendocrine Neoplasm1
  • Pancreatic Neuroendocrine Neoplasm1
  • Lung Neuroendocrine Neoplasm1
  • Malignant Solid Neoplasm1
  • Lung Cancer1

Buffalo, New York1 trial

Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas

Roswell Park Cancer Institute

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.